inclusion criteria: 1. healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment. 2. women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination. 3. able to understand the content and possible risks of informed consent and willing to sign the informed consent form (icf). 4. able to understand and agrees to comply with all study procedures and be available for all study visits. 5. negative serological test for hepatitis b surface antigen (hbsag), hcv rna and hiv antibody screening. 6. negative in serum antibodies (igg) against sars-cov-2 elisa. 7. negative result of rt-pcr screening of nasopharyngeal or throat swabs for sars-cov-2. 8. ear temperature ≤ 38.0°c. 9. the body mass index (bmi) of 18-30 kg/m2, inclusive, at screening. 10. indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators. 11. judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ecg, vital signs, and clinical laboratory tests performed at screening.

inclusion criteria: 1. healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment. 2. women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination. 3. able to understand the content and possible risks of informed consent and willing to sign the informed consent form (icf). 4. able to understand and agrees to comply with all study procedures and be available for all study visits. 5. negative serological test for hepatitis b surface antigen (hbsag), hcv rna and hiv antibody screening. 6. negative in serum antibodies (igg) against sars-cov-2 elisa. 7. negative result of rt-pcr screening of nasopharyngeal or throat swabs for sars-cov-2. 8. ear temperature ≤ 38.0°c. 9. the body mass index (bmi) of 18-30 kg/m2, inclusive, at screening. 10. indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators. 11. judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ecg, vital signs, and clinical laboratory tests performed at screening.

inclusion criteria: healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment. women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination. able to understand the content and possible risks of informed consent and willing to sign the informed consent form (icf). able to understand and agrees to comply with all study procedures and be available for all study visits. negative serological test for hepatitis b surface antigen (hbsag), hcv rna and hiv antibody screening. negative in serum antibodies (igg) against sars-cov-2 elisa. negative result of rt-pcr screening of nasopharyngeal or throat swabs for sars-cov-2. ear temperature ≤ 38.0°c. the body mass index (bmi) of 18-30 kg/m2, inclusive, at screening. indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators. judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ecg, vital signs, and clinical laboratory tests performed at screening.

inclusion criteria: healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment. women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination. able to understand the content and possible risks of informed consent and willing to sign the informed consent form (icf). able to understand and agrees to comply with all study procedures and be available for all study visits. negative serological test for hepatitis b surface antigen (hbsag), hcv rna and hiv antibody screening. negative in serum antibodies (igg) against sars-cov-2 elisa. negative result of rt-pcr screening of nasopharyngeal or throat swabs for sars-cov-2. ear temperature ≤ 38.0°c. the body mass index (bmi) of 18-30 kg/m2, inclusive, at screening. indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators. judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ecg, vital signs, and clinical laboratory tests performed at screening.

inclusion criteria: 1. healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment. 2. women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination. 3. able to understand the content and possible risks of informed consent and willing to sign the informed consent form (icf). 4. able to understand and agrees to comply with all study procedures and be available for all study visits. 5. negative serological test for hepatitis b surface antigen (hbsag), hcv rna and hiv antibody screening. 6. negative in serum antibodies (igg) against sars-cov-2 elisa. 7. negative result of rt-pcr screening of nasopharyngeal or throat swabs for sars-cov-2. 8. ear temperature ≤ 38.0°c. 9. the body mass index (bmi) of 18-30 kg/m2, inclusive, at screening. 10. indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators. 11. judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ecg, vital signs, and clinical laboratory tests performed at screening.

inclusion criteria: 1. healthy male or non-pregnant female between the age of 20 and 55 years at time of enrollment. 2. women of childbearing potential and men must agree to practice medically effective contraception from first vaccination until 3 months after the last vaccination. 3. able to understand the content and possible risks of informed consent and willing to sign the informed consent form (icf). 4. able to understand and agrees to comply with all study procedures and be available for all study visits. 5. negative serological test for hepatitis b surface antigen (hbsag), hcv rna and hiv antibody screening. 6. negative in serum antibodies (igg) against sars-cov-2 elisa. 7. negative result of rt-pcr screening of nasopharyngeal or throat swabs for sars-cov-2. 8. ear temperature ≤ 38.0°c. 9. the body mass index (bmi) of 18-30 kg/m2, inclusive, at screening. 10. indexes of blood routine, biochemistry and other laboratory tests are within the normal ranges, or not clinically significant as judged by investigators. 11. judged to be healthy by the investigator on the basis of medical history, physical examination, 12-lead ecg, vital signs, and clinical laboratory tests performed at screening.